Efficacy and safety of patients immunization with chronic obstructive pulmonary disease with monoclonal antibodies
Background. Chronic obstructive pulmonary disease (COPD) is characterized by a high level of morbidity and mortality and is associated with significant social and economic damage to the health system and society. COPD and COVID-19 have many potentially negative relationships that can lead to worse o...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
"Consilium Medicum" Publishing house
2023-04-01
|
| Series: | Терапевтический архив |
| Subjects: | |
| Online Access: | https://ter-arkhiv.ru/0040-3660/article/viewFile/346667/118473 |
| _version_ | 1797634648125210624 |
|---|---|
| author | Vladimir N. Antonov Galina L. Ignatova |
| author_facet | Vladimir N. Antonov Galina L. Ignatova |
| author_sort | Vladimir N. Antonov |
| collection | DOAJ |
| description | Background. Chronic obstructive pulmonary disease (COPD) is characterized by a high level of morbidity and mortality and is associated with significant social and economic damage to the health system and society. COPD and COVID-19 have many potentially negative relationships that can lead to worse outcomes of COVID-19, including impaired lung function, old age and the presence of concomitant diseases
Aim. To assess efficacy and safety of the drug Tixagevimab + Cilgavimab for the pre-contact prevention of COVID-19 infection in patients with COPD.
Material and methods. A total of 324 male patients were included in the study, who were treated or monitored at the Regional Clinic Hospital №3 and the Regional Pulmonological Center of Chelyabinsk in AprilMay 2022. The main endpoints of observation, for 3 and 6 months, to assess the effectiveness were the dynamics of shortness of breath according to The Modified Medical Research Council Dyspnea Scale mMRC, the The forced expiratory volume in 1 second, the number of exacerbations, emergency calls, hospitalizations, polymerase chain reaction for SARS-CoV-2. Local and general reactions after immunization were evaluated. The drug Evusheld (150 mg Tixsagevimab +150 mg Cilgavimab, AstraZeneca) was used for immunization.
Results and conclusion. The effectiveness of pre-contact prevention of COVID-19 was 88.8%. The administration of the drug does not provoke an exacerbation of the underlying disease. The main clinical and functional indicators have positive dynamics by the 6th month of follow-up. The drug is well tolerated and has no significant both early and late complications. |
| first_indexed | 2024-03-11T12:10:36Z |
| format | Article |
| id | doaj.art-4ab316afbdab4977bb58ebb14cc42366 |
| institution | Directory Open Access Journal |
| issn | 0040-3660 2309-5342 |
| language | Russian |
| last_indexed | 2024-03-11T12:10:36Z |
| publishDate | 2023-04-01 |
| publisher | "Consilium Medicum" Publishing house |
| record_format | Article |
| series | Терапевтический архив |
| spelling | doaj.art-4ab316afbdab4977bb58ebb14cc423662023-11-07T13:56:01Zrus"Consilium Medicum" Publishing houseТерапевтический архив0040-36602309-53422023-04-0195324324710.26442/00403660.2023.03.20214678271Efficacy and safety of patients immunization with chronic obstructive pulmonary disease with monoclonal antibodiesVladimir N. Antonov0https://orcid.org/0000-0002-3531-3491Galina L. Ignatova1https://orcid.org/0000-0002-0877-6554South Ural State Medical UniversitySouth Ural State Medical UniversityBackground. Chronic obstructive pulmonary disease (COPD) is characterized by a high level of morbidity and mortality and is associated with significant social and economic damage to the health system and society. COPD and COVID-19 have many potentially negative relationships that can lead to worse outcomes of COVID-19, including impaired lung function, old age and the presence of concomitant diseases Aim. To assess efficacy and safety of the drug Tixagevimab + Cilgavimab for the pre-contact prevention of COVID-19 infection in patients with COPD. Material and methods. A total of 324 male patients were included in the study, who were treated or monitored at the Regional Clinic Hospital №3 and the Regional Pulmonological Center of Chelyabinsk in AprilMay 2022. The main endpoints of observation, for 3 and 6 months, to assess the effectiveness were the dynamics of shortness of breath according to The Modified Medical Research Council Dyspnea Scale mMRC, the The forced expiratory volume in 1 second, the number of exacerbations, emergency calls, hospitalizations, polymerase chain reaction for SARS-CoV-2. Local and general reactions after immunization were evaluated. The drug Evusheld (150 mg Tixsagevimab +150 mg Cilgavimab, AstraZeneca) was used for immunization. Results and conclusion. The effectiveness of pre-contact prevention of COVID-19 was 88.8%. The administration of the drug does not provoke an exacerbation of the underlying disease. The main clinical and functional indicators have positive dynamics by the 6th month of follow-up. The drug is well tolerated and has no significant both early and late complications.https://ter-arkhiv.ru/0040-3660/article/viewFile/346667/118473chronic obstructive pulmonary diseasecovid-19passive immunizationtixagevimab + cilgavimab |
| spellingShingle | Vladimir N. Antonov Galina L. Ignatova Efficacy and safety of patients immunization with chronic obstructive pulmonary disease with monoclonal antibodies Терапевтический архив chronic obstructive pulmonary disease covid-19 passive immunization tixagevimab + cilgavimab |
| title | Efficacy and safety of patients immunization with chronic obstructive pulmonary disease with monoclonal antibodies |
| title_full | Efficacy and safety of patients immunization with chronic obstructive pulmonary disease with monoclonal antibodies |
| title_fullStr | Efficacy and safety of patients immunization with chronic obstructive pulmonary disease with monoclonal antibodies |
| title_full_unstemmed | Efficacy and safety of patients immunization with chronic obstructive pulmonary disease with monoclonal antibodies |
| title_short | Efficacy and safety of patients immunization with chronic obstructive pulmonary disease with monoclonal antibodies |
| title_sort | efficacy and safety of patients immunization with chronic obstructive pulmonary disease with monoclonal antibodies |
| topic | chronic obstructive pulmonary disease covid-19 passive immunization tixagevimab + cilgavimab |
| url | https://ter-arkhiv.ru/0040-3660/article/viewFile/346667/118473 |
| work_keys_str_mv | AT vladimirnantonov efficacyandsafetyofpatientsimmunizationwithchronicobstructivepulmonarydiseasewithmonoclonalantibodies AT galinalignatova efficacyandsafetyofpatientsimmunizationwithchronicobstructivepulmonarydiseasewithmonoclonalantibodies |